About us
At a Glance
Axon Neuroscience is a clinical-stage biotech company developing disease-modifying immunotherapeutics for Alzheimer's disease and Frontotemporal lobar degeneration. Ground-breaking discoveries in Alzheimer’s disease research made by AXON Neuroscience enabled the company to create a therapeutic platform of global importance. The target products of strategic importance in this platform are revolutionary therapeutic candidate vaccines for treatment of Alzheimer's disease and Frontotemporal lobar degeneration.
AXON Neuroscience has developed unique animal models that reproduce Alzheimer’s disease and allow for a swift and effective pre-clinical validation of efficacy of new therapeutics and pre-clinical evaluation of diagnostic tools.
Strategically targeted research and development enable AXON Neuroscience to prepare for future production of an extensive assortment of disease modifying pharmaceuticals and diagnostic methods for Alzheimer’s disease.
— Michal Fresser, CEO Axon Neuroscience"Alzheimer’s disease has long been the modern plague of mankind. Despite momentous efforts across the industry, an effective prevention and treatment has not yet been discovered. Axon is on a mission to change this. With over two decades of dedicated research, our expert team is leading industry on the path to finding a tau based treatment. The very positive results from our landmark Phase II trial underpin our confidence, and strengthen our motivation to get a treatment to patients as soon as possible."
Mission
- 7,6 billion worldpopulation
- 636 million world population over 65
- 47 million dementia cases
The mission of AXON Neuroscience is to discover and deliver disease modifying immunotherapeutics and enhance the quality of life for patients suffering from Alzheimer's disease and Frontotemporal lobar degeneration.
Leadership
Michal Fresser, Chief Executive Officer
Michal Fresser first joined Axon in 2013 as a board member & general counsel to the firm. Since then, he has been appointed as Chief Executive Officer of Axon in 2019, while he also serves as Chairman of the Board of Directors of Axon’s two subsidiaries – Axon Neuroscience CRM Services SE and Axon Neuroscience R&D Services SE.
Prior to his arrival at Axon, Michal had established a career in both legal advisory and consulting. There, he covered multiple sectors, gaining extensive knowledge on mergers and acquisitions, cross-border transactions, and both corporate and competition law.
Norbert Žilka, Chief Science Officer
Norbert has been with Axon since its establishment in 1999. He has played a key role in guiding discoveries and has helped transform Axon’s portfolio of products, which eventually led to his appointment as CSO in 2015.
He has co-authored the project Synaptic Dysfunction in Alzheimer’s Disease (Marie Curie Innovative Training Network). In addition, he serves as the national coordinator and Chairman of the Neuroscience session at the first Frontiers of Science Meeting.
Norbert holds a PhD in Immunology from the Slovak Academy of Sciences (SAS) and is an associate professor at the Institute of Neuroimmunology at SAS.
Ladislav Satko, Chief Financial Officer
Ladislav Satko has over fifteen years’ experience leading finance and operations for international businesses. In 2003, Ladislav worked in a financial role for a European construction business. Following this, he was Head of Finance for one of the largest central European publicly traded real estate companies.
In November 2011 he was appointed as Chief Financial Officer of Axon, where he is responsible for financial, human resources and IT matters at the company.
Ladislav holds a Master’s degree in Business Administration from the Economic University in Bratislava.
Roman Sivak, Managing Director of AXON Neuroscience CRM and R&D
Roman serves as Managing Director of Axon’s two subsidiaries – Axon Neuroscience CRM Services SE and AXON Neuroscience R&D Services SE, having previously been in a role as CEO of Axon from 2011 until 2019.
He has extensive experience in the financial sector and has served in various management positions for start-up projects and acquisitions. He has also served as a member of supervisory boards of multiple start-up projects and acquisitions in industrial and financial sectors.
Roman graduated with a Master of Economics degree from the University of Economics in Bratislava.
Prof. Michal Novák, Co-Founder of AXON Neuroscience
Prof. Novak is a serving board member for Axon, having co-founded the company in 1999.
He is a world-renowned scientist, and prior to founding Axon, spent 10 years at the Laboratory of Molecular Biology in Cambridge in a team with three Nobel Laureates. There, Prof. Novak created a monoclonal antibody (MN423), which has driven revolutionary discoveries towards the understanding the role of tau protein in Alzheimer’s disease.
Prof. Novak is also the founder of The Institute of Neuroimmunology of the Slovak Academy of Sciences, The Memory Foundation, The Slovak Alzheimer’s Association and the Slovak Society for Neuroscience, while also serving as the co-founder of the EU Joint Programme- Neurodegenerative Disease Research (JPND). In 2016, he was awarded with the World Health Organisation’s prize for Research in Health Care for the Elderly and in Health Promotion.
Advisory Board
AXON Neuroscience has assembled an international team of leading experts in the field of Alzheimer’s disease and clinical drug development to support the designs, conducts, and analyses of AXON Neuroscience clinical trials for new treatments of Alzheimer’s disease and other related neurodegenerative disorders.
Bengt Winblad
MD, Prof., Division of Neurogeriatrics, Karolinska Inst., Stockholm, SE
Philip Scheltens
Dr, Prof., Director of Alzheimer center, VUmc, Amsterdam, NL
Howard Feldman
MD, FRCP(C), Director of UC San Diego ADCS, San Diego, USA
John Harrison
Assoc Prof., Alzheimer center, VUmc, Amsterdam, NL/UK
Khalid Iqbal
Professor and Chairman, Department of Neurochemistry, at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA
Richard Kay
Expert in Statistics, an Honorary Visiting Professor at the School of Pharmacy, University of Cardiff and a member of the Faculty of Pharmaceutical Medicine. Editor of the journal Pharmaceutical Statistics.
Reinhold Schmidt
Univ.-Prof. Dr.med.univ , Universitätsklinik für Neurologie, Graz, AT
Lutz Frölich
MD, Prof., Head of Clinics of Gerontopsychiatry, Mannheim, GE
Jakub Hort
MD, Prof., Head of Counseling Center for Cognitive Disfunctions, FN Motol, Prague, CZ
Kaj Blennow
Head of Research on Neurochemical Pathogenesis and Diagnostics at the University of Gothenburg
Axon's Story
AXON Neuroscience initiatied its Phase 1 study in patients with non-fluent variant of primary progressive aphasia and enrolled the first patient.
April 2017
AXON Neuroscience published the results of the Phase 1 study of its active vaccine AADvac1 in patients with Alzheimer’s disease.
June 2016
AXON Neuroscience becomes a founding member of the Society for CSF Analysis and Clinical Neurochemistry
March 2016
AXON Neuroscience attended the Clinical Trials on Alzheimer´s Disease conference (CTAD) in Barcelona, on November 5-7, 2015
July 2015
AXON Neuroscience successfully finished phase 1 Study with AADvac1
December 2014
AXON Neuroscience and MRC Technology announced successful humanization of Anti-Tau Monoclonal Antibody for Alzheimer’s disease therapy. See Press Release for more information)
July 2014
Axon Neuroscience has received final approval from the Regulatory Authority and Central Ethics Committee in Graz to start a AADvac1 phase I follow-up study
July 2013
First-in-man clinical trial with the first active immunotherapy directed against neurofibrillary tau pathology in Alzheimer’s disease was approved by the Regulatory Authority and Central Ethics Committee in Graz
March 2013
AXON Neuroscience started GMP (good manufacturing practice) vaccine production and finished its GLP (good laboratory practice) toxicology and safety pharmacology studies
2009-2011
AXON Neuroscience uncovered the mechanism of how Alzheimer tau induces neuroinflammation
AXON Neuroscience discovered the most vulnerable area of Alzheimer tau - the Achilles heel of Alzheimer tau
Using knowledge of the 3D structure of the tau Achilles heel, AXON Neuroscience produced tau peptide vaccines
2007
AXON Neuroscience showed that Alzheimer tau is an inducer of oxidative stress
2003
AXON Neuroscience has developed an integrated set of new immunological, biochemical, and cell assays devoted to drug screening and validation
2001
AXON Neuroscience was founded as a biotech company focusing on Alzheimer's disease therapy (Michal Novak was a co-founder of the company)
1994
Michal Novak discovered tau truncation as the most productive post-translational modification in Alzheimer's disease and simultaneously designated truncated tau as a driving force of the neurofibrillary degeneration in Alzheimer's disease
1988
August 2017
AXON Neuroscience has completed patients’ recruitment in the phase II study ADAMANT in patients with Alzheimer’s disease.
December 2016
AXON Neuroscience has started the Phase II study as the first patient has been vaccinated with the active tau vaccine AADvac1.
April 2016
AXON Neuroscience presented at the 14th Springfield Symposium on Advances in Alzheimer Therapy two topics from its disease modifying AD program. See Press Release for more information
November 2015
AXON Neuroscience as a gold level sponsor has organized a Symposium at the Alzheimer´s Association International Conference (AAIC), the largest Alzheimer´s and dementia conference in the world, in Washington, D.C.
March 2015
Recruitment of patients for AADvac1 phase I study has been completed
August 2014
Prof. Michal Novak presented new clinical data from the ongoing AADvac1 phase I study at the Alzheimer Association International Conference in Copenhagen (July 12-17, 2014)
December 2013
The first patient was vaccinated with AADvac1
May 2013
AXON Neuroscience presented its therapeutic strategies at the AD/PD 2013 international conference in Florence
2012
AXON Neuroscience confirmed the in vivo efficacy of its vaccines in preclinical studies using AD transgenic rat models
2009
AXON Neuroscience initiated a revolutionary immunotherapy program
2006
AXON Neuroscience developed the first AD transgenic rat model and validated Alzheimer tau as a major cause of AD neurodegeneration. The model was presented in the "Hot Topics Session" at the 9th International Conference on AD (ICAD), Philadelphia in July 2004
2002
AXON Neuroscience discovered and characterized a particular form of the truncated tau protein with a causal role in AD - Alzheimer tau
1999
Michal Novak proposed that truncated tau species display features similar to prions and therefore he designated them as tauons
1991
While working with three Nobel Laureates - Cesar Milstein, Aaron Klug and John Walker - at MRC LMB Cambridge, UK, Michal Novak created a monoclonal antibody (MN423) that was instrumental in the discovery of tau protein as an integral constituent of neurofibrillary tangles – a major hallmark of Alzheimer's disease
Research & Development
Discovery Programs
Alzheimer Tau
AXON Neuroscience has more than 500 cumulative years of experience in neuroimmunology research. AXON Neuroscience has developed a novel approach using monoclonal antibodies as structural imprints of diseased forms of tau proteins isolated from Alzheimer's disease brains. These imprints have been used to identify a novel target for AD therapy – Alzheimer tau.
AXON Alzheimer‘s disease immunotherapy program (ADIP)
AXON Neuroscience is developing new immunotherapeutics targeting Alzheimer tau that can prevent the formation of tau oligomers and neurofibrillary tangles and thus protect the brain from neurodegeneration. These therapeutic approaches have been tested in preclinical studies in AXON animal models. AXON Neuroscience developed active and passive vaccines that eliminate Alzheimer tau by targeting its most vulnerable part.
AXON Alzheimer's disease diagnostic program (ADDP)
AXON Neuroscience discovered a novel pathological form of tau protein critical for development of AD and present only in AD patients. Based on this knowledge, AXON Neuroscience is developing new diagnostic tools for early and late stages of AD.
AXON Alzheimer's disease preclinical platforms (ADPP)
AXON Neuroscience has generated transgenic rat and mouse models recapitulating the main pathological features of Alzheimer's disease such as neurofibrillary degeneration, neuroinflammation, synaptic failure, oxidative stress, and neurobehavioural changes. The models are used for preclinical efficacy studies with AXON active and passive vaccines, identification of novel diagnostic biomarkers in the cerebrospinal fluid and blood, and for development of anti-inflammatory AD therapy.
-
AXON bio-fluid diagnostic platform
AXON animal models are critical for identification of potential diagnostic proteome and peptidome-based disease-specific biomarkers in cerebrospinal fluid.
-
AXON in-flame platform
AXON animal models are ideally suited for validation of new drugs targeting specific inflammatory pathways involved in Alzheimer's disease.
AXON Frontotemporal lobar degeneration immunotherapy program
An estimated 20% of patients affected by dementia suffer from Frontotemporal lobar degeneration (FTLD). Our preclinical studies showed that tau Achilles heel is involved in the pathogenesis of FTLD and thus represents a specific target for immunotherapy. AXON Neuroscience has launched a clinical trial on AADvac1 vaccine in patients suffering from non-fluent variant of nfvPPA.
Intellectual Property
AXON Neuroscience holds intellectual property rights:
- to pathologically modified tau species derived from Alzheimer's disease brain tissues – the Alzheimer tau family – that directly correlate with the cognitive decline of AD patients
- to the use of Alzheimer tau as a therapeutic drug target
- to unique therapeutic and diagnostic antibodies, as well as their fragments, portions, and derivatives that bind specific regions of the Alzheimer tau protein responsible for the initiation and propagation of pathological tau-tau interactions
- to methods of using these antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related human tauopathies
- to antibodies and/or peptide vaccines that elicit an immune response directed to pathological tau proteins and tau deposits in patient brains
- to transgenic non-human animal models expressing the Alzheimer tau protein
Publications
AXON Neuroscience has published a number of valuable original research papers in several prestigious scientific journals. The papers focus on structural neuroscience, neuroimmunology and neuroproteomics of Alzheimer's disease.
Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial
Novak P et al.
Lancet Neurology, 2016
- Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease
- Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M.
- Alzheimers Res Ther. 2014 Aug 1;6(4):45.
- First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model
- Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M.
- Alzheimers Res Ther. 2014 Aug 1;6(4):44.
- Can we teach old dogs new tricks? Neuroprotective cell therapy in Alzheimer's and Parkinson's disease.
- Kazmerova Z, Zilka N, Cente M, Neradil P, Zilkova M, Novak M.
- J Alzheimers Dis. 2013; 37(2):251-72
- Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways
- Zilka N, Kazmerova Z, Jadhav S, Neradil P, Madari A, Obetkova D, Bugos O, Novak M.
- J Neuroinflamm. 2012; 9:47
- Chaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy
- Kontsekova E, Ivanovova N, Handzusova M, Novak M.
- Cell Mol Neurobiol. 2009; 29:793-798
- Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies
- Zilka N, Kontsekova E, Novak M.
- J Alzheimers Dis. 2008; 15(2):169-79.
- Of rodents and men: the mysterious interneuronal pilgrimage of misfolded protein tau in Alzheimer’s disease.
- Levarska L, Zilka N, Jadhav S, Neradil P, Novak M.
- J Alzheimers Dis. 2013; 37(3):569-77
- Immunomodulation of Memory-Impairing Protein Tau in Alzheimer's Disease
- Zilka N, Stozicka Z, Kazmerova Z, Cente M, Kovacech B, Novak M.
- Neurodegenerative Dis. 2012; 10:242-245
- First transgenic rat model developing progressive cortical neurofibrillary tangles
- Filipcik P, Zilka N, Bugos O, Kucerak J, Koson P, Novak P, Novak M.
- Neurobiol Aging 2012; 33:1448-1456
- Hyperphosphorylated truncated protein tau induces caspase 3 independent apoptotic-like pathway in the AD cellular model
- Zilkova M, Zilka N, Kovac A, Kovacech B, Skrabana R, Skrabanova M, Novak M.
- J Alzheimers Dis. 2011; 23:161-173
- Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease
- Stozicka Z, Zilka N, Novak P, Kovacech B, Bugos O, Novak M.
- J Neuroinflamm. 2010; 7:64
- CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy
- Zilka N, Korenova M, Kovacech B, Iqbal K, Novak M.
- Acta Neuropath. 2010; 119:679-387
- Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies
- Zilka N, Korenova M, Novak M.
- Acta Neuropath. 2009; 118:71-86
- Expression of a truncated human tau protein induces aqueous-phase free radicals in a rat model of tauopathy – implications for targeted antioxidative therapy
- Cente M, Filipcik P, Mandakova S, Zilka N, Krajciova G, Novak M.
- J Alzheimers Dis. 2009; 17:913-920
- Beyond the rat models of human neurodegenerative disorders
- Bugos O, Bhide M, Zilka N.
- Cell Mol Neurobiol. 2009; 29:859-869
- Memantine Prevents Sensitivity to Excitotoxic Cell Death of Rat Cortical Neurons Expressing Human Truncated
Tau Protein - Cente M, Mandakova S, Filipcik P.
- Cell Mol Neurobiol. 2009; 29:945-949
- Cortical and Hippocampal Neurons from Truncated Tau Transgenic Rat Express Multiple Markers of Neurodegeneration
- Filipcik P, Cente M, Krajciova G, Vanicky I, Novak M.
- Cell Mol Neurobiol. 2009; 29:895-900
- Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic
rat model of tauopathy - Zilka N, Stozicka Z, Kovac A, Pilipcinec E, Bugos O, Novak M.
- J Neuroimmunol. 2009; 209 (1-2):16-25.
- NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model
of tauopathy - Korenova M, Zilka N, Stozicka Z, Bugos O, Vanicky I, Novak M.
- J Neurosci Methods. 2009; 177(1):108-14.
- Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss
or correlating with terminal neurofibrillary tangle load - Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M.
- Eur J Neurosci. 2008; 28(2):239-46.
- Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment
in transgenic rats - Hrnkova M, Zilka N, Minichova Z, Koson P, Novak M.
- Brain Res. 2007; 1130(1):206-13.
- Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy
- Cente M, Filipcik P, Pevalova M, Novak M.
- Eur J Neurosci. 2006; 24(4):1085-90.
- N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization
- Paholikova K, Salingova B, Opattova A, Skrabana R, Majerova P, Zilka N, Kovacech B, Zilkova M, Barath P, Novak M.
- J Alzheimers Dis. 2015;43(3):915-26.
- Microglia display modest phagocytic capacity for extracellular tau oligomers.
- Majerova P, Zilkova M, Kazmerova Z, Kovac A, Paholikova K, Kovacech B, Zilka N, Novak M.
- J Neuroinflammation. 2014 Sep 13;11(1):161.
- Liquid chromatography-tandem mass spectrometry method for determination of panel of neurotransmitters in cerebrospinal fluid from the rat model for tauopathy
- Kovac A, Somikova Z, Zilka N, Novak M.
- Talanta. 2014 Feb;119:284-90.
- Liquid Chromatography-Tandem Mass Spectrometry Method for Determination of Homocysteine in Rat Plasma: Application to the Study of a Rat Model for Tauopathies
- Kovac A, Svihlova K, Michalicova A, Novak M.
- J Chromatogr Sci. 2014 Dec 2.
- Liquid chromatography-tandem mass spectrometry method for determination of panel of neurotransmitters in cerebrospinal fluid from the rat model for tauopathy
- Kovac A, Somikova Z, Zilka N, Novak M.
- Talanta. 2014; 119:284-90
- Protein truncation as a common denominator of human neurodegenerative foldopathies.
- Jadhav S, Zilka N, Novak M.
- Mol Neurobiol. 2013; 48(3):516-32
- Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome
- Opattova A, Filipcik P, Cente M, Novak M.
- J Alzheimers Dis. 2013; 33(2):339-48.
- Crystallization and preliminary X-ray diffraction analysis of two peptides from Alzheimer PHF in complex with the MN423 antibody Fab fragment
- Skrabana R, Cehlar O, Flachbartova Z, Kovac A, Sevcik J, Novak M.
- Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012; 68(Pt 10):1186-90.
- Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody Fab fragments
- Cehlar O, Skrabana R, Kovac A, Kovacech B, Novak M.
- Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012; 68(Pt 10):1181-5.
- The self-perpetuating tau truncation circle
- Zilka N, Kovacech B, Barath P, Kontsekova E, Novak M.
- Biochem Soc Trans. 2012; 40:681-686
- Misfolded Truncated Protein tau Induces Innate Immune Response via MAPK Pathway
- Kovac A, Zilka N, Kazmerova Z, Cente M, Zilkova M, Novak M.
- J Immunol. 2011; 187:2732-2739
- Tau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer's Disease
- Kovacech B, Novak M.
- Curr Alz Res. 2010; 7: 708-716
- Monoclonal antibody MN423 as a stable mold facilitates structure determination of disordered tau protein
- Skrabana R, Dvorsky R, Sevcik J, Novak M.
- J Struct Biol. 2010; 171: 74-81
- Transition of Tau Protein from Disordered to Misordered in Alzheimer's Disease
- Kovacech B, Skrabana R, Novak M.
- Neurodegenerative Dis. 2010; 7:24-27
- New age of neuroproteomics in Alzheimer's disease research
- Kovacech B, Zilka N, Novak M.
- Cell Mol Neurobiol. 2009; 29:799-805
- Structure solution of misfolded conformations adopted by intrinsically disordered Alzheimer's tau protein
- Sevcik J, Skrabana R, Kontsekova E, Novak M.
- Protein Pept Lett. 2009; 16(1):61-4.
- Rat tau proteome consists of six tau isoforms: Implication for animal models of human tauopathies
- Hanes J, Zilka N, Bartkova M, Caletkova M, Dobrota D, Novak M.
- J Neurochem. 2009; 108, 1167–1176.
- Preserving free thiols of intrinsically disordered tau protein without the use of a reducing agent
- Krajciova G, Skrabana R, Filipcik P, Novak M.
- ANALYTICAL BIOCHEMISTRY. 2008; 383(2):343-345.
- High-yield purification of fetal tau preserving its structure and phosphorylation pattern
- Ivanovova N, Handzusova M, Hanes J, Kontsekova E, Novak M.
- J Immunol Methods. 2008; 339(1):17-22.
- X-ray structure of the PHF core C-terminus: insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease
- Sevcik J, Skrabana R, Dvorsky R, Csokova N, Iqbal K, Novak M.
- FEBS Lett. 2007; 581(30):5872-8.
- A novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised in human brain
- Kovacech B, Kontsekova E, Zilka N, Novak P, Skrabana R, Filipcik P, Iqbal K, Novak M.
- FEBS Lett. 2007; 581(4):617-22.
- Preparation, crystallization and preliminary X-ray analysis of the Fab fragment of monoclonal antibody MN423, revealing the structural aspects of Alzheimer's paired helical filaments
- Csokova N, Skrabana R, Urbanikova L, Kovacech B, Sevcik J, Novak M.
- Protein Pept Lett. 2006; 13(9):941-4.
- Alzheimer's-disease-associated conformation of intrinsically disordered tau protein studied by intrinsically disordered protein liquid-phase competitive enzyme-linked immunosorbent assay
- Skrabana R, Skrabanova-Khuebachova M, Kontsek P, Novak M.
- Anal Biochem. 2006; 359(2):230-7.
- Intrinsically disordered proteins in the neurodegenerative processes: formation of tau protein paired helical filaments and their analysis
- Skrabana R, Sevcik J, Novak M.
- Cell Mol Neurobiol. 2006; 26(7-8):1085-97.
- First insert of tau protein is present in all stages of tau pathology in Alzheimer's disease
- Soltys K, Rolkova G, Vechterova L, Filipcik P, Zilka N, Kontsekova E, Novak M.
- Neuroreport. 2005; 16(15):1677-81.
- Alzheimer paired helical filaments (PHFs) studied by high-resolution TEM: what can vertical Pt-C replication tell us about the organization of the pronase-digested PHF core?
- Ruben GC, Novak M, Edwards PC, Iqbal K.
- Microsc Res Tech. 2005; 67(3-4):196-209.
- Folding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423
- Skrabana R, Kontsek P, Mederlyova A, Iqbal K, Novak M.
- FEBS Lett. 2004; 568(1-3):178-82.
- Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases
- Csokova N, Skrabana R, Liebig HD, Mederlyova A, Kontsek P, Novak M.
- Protein Expr Purif. 2004; 35(2):366-72.
- DC11: a novel monoclonal antibody revealing Alzheimer's disease-specific tau epitope
- Vechterova L, Kontsekova E, Zilka N, Ferencik M, Ravid R, Novak M.
- Neuroreport. 2003 Jan 20;14(1):87-91.
- Mapping the C terminal epitope of the Alzheimer's disease specific antibody MN423
- Khuebachova M, Verzillo V, Skrabana R, Ovecka M, Vaccaro P, Panni S, Bradbury A, Novak M.
- J Immunol Methods. 2002 Apr 1;262(1-2):205-15.
Clinical trials
Klinische Prüfungen
Klinické skúšania
Klinické hodnocení
AADvac1 Phase I Study in Alzheimer’s disease
This first- in-man phase I study was designed to assess the safety and tolerability of AADvac1 for the treatment of Alzheimer's disease. Efficacy was assessed in an exploratory manner.
AADvac1 is an active immunotherapy directed against pathologically modified Alzheimer tau protein that is the main constituent of neurofibrillary tangles (NFTs). It is intended to be a disease-modifying treatment for Alzheimer's disease, aiming to halt its progress.
This AADvac1 phase 1 clinical trial in AD has been completed in March 2015.
The results of the study were published in Lancet Neurology in December 2016.
Novak P et al., “Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial”, Lancet Neurology, 2016. More info
The study was carried out in accordance with the ethical and scientific principles of Declaration of Helsinki, the ICH Guideline on Good Clinical Practice, the EU Clinical Trials Directive, as well as local regulations.
The Data Safety Monitoring Board consisting of internationally recognized medical and scientific experts has been established to assess the safety and tolerability profile of AADvac1 in AD phase 1 clinical trial.
Additional information can be found on: http://www.clinicaltrials.gov/ct2/show/NCT01850238
Study Sites in Austria:
Wien
Salzburg
Graz
Universitätsklinik für Neurologie, PMU, Christian-Doppler Klinik
Salzburg, Austria, 5020 
www.salk.at
Wolfgang Staffen, Professor
Medizinische Universität Wien
- Wien, Austria, 1090
- www.meduniwien.ac.at
- Peter Dal-Bianco, Professor
Sozialmedizinisches Zentrum Ost Donauspital
- Wien, Austria, 1220
- www.wienkav.at/kav/dsp/
- Michael Rainer, Dozent
AADvac1 Phase 1 Follow up Study in Alzheimer’s disease
The 18-month follow-up study was designed to assess the long term safety and tolerability of AADvac1 in the treatment of Alzheimer's disease as well as persistence of the immune response to AADvac1 in patients who have completed the AADvac1 phase I study.
AADvac1 is an active immunotherapy directed against pathologically modified Alzheimer tau protein that is the main constituent of neurofibrillary tangles (NFTs). It is intended to be a disease-modifying treatment for Alzheimer's disease, aiming to halt its progress.
The study was completed in August 2016.
Approvals:
The study was carried out in accordance with the ethical and scientific principles of Declaration of Helsinki, the ICH Guideline on Good Clinical Practice, the EU Clinical Trials Directive, as well as local regulations.
Data Safety Monitoring Board consisting of internationally recognized medical and scientific experts has been established to assess the safety and tolerability profile of AADvac1 in AD Follow up Study.
Additional information can be found on: http://www.clinicaltrials.gov/ct2/show/NCT02031198
Study Sites in Austria:
Wien
Salzburg
Graz
Universitätsklinik für Neurologie, PMU, Christian-Doppler Klinik
- Salzburg, Austria, 5020
- www.salk.at
- Wolfgang Staffen, Professor
Medizinische Universität Wien
- Wien, Austria, 1090
- www.meduniwien.ac.at
- Peter Dal-Bianco, Professor
Sozialmedizinisches Zentrum Ost Donauspital
- Wien, Austria, 1220
- www.wienkav.at/kav/dsp/
- Michael Rainer, Dozent
AADvac1 AD Phase II Study
AADvac1 AD Phase II Studie
Skúšanie AADvac1 AD Fáza II
Hodnocení AADvac1 AD Fáze II
Back to map
Univerzitná nemocnica L. Pasteura Košice
Psychiatrická klinika- Rastislavova 43, 041 90 Košice
- www.unlp.sk
- Slávka Dubinská, MD
MUDr. Beáta Dupejová, neurologická ambulancia s.r.o.
- Nová ulica 21, 974 04 Banská Bystrica
- www.dupejova.sk
- Beáta Dupejová, MD
Fakultná nemocnica s poliklinikou Žilina
- Psychiatrické oddelenie
- ul. Vojtecha Spanyola 43, 012 07 Žilina
- www.fnspza.sk
- Martina Hanzelová, MD
Neštátna psychiatrická ambulancia
- Mýtna 5, 811 07 Bratislava
- www.poliklinikamytna.sk
- Eva Janíková, MD
Centrum zdravia R.B.K., s.r.o.
- Psychiatrická ambulancia
- MUDr. Pribulu 148, 089 01 Svidník
- www.centrumzdravia-rbk.sk
- Rastislav Korba, MD
Univerzitná nemocnica Bratislava, Nemoc. Staré Mesto
- I.Neurologická klinika LF UK a UNB
- Mickiewiczova 13, 813 69 Bratislava
- www.unb.sk
- Peter Turčáni, Prof., MD, PhD.
Univerzitná nemocnica Bratislava, Nemoc. Staré Mesto
- Psychiatrická klinika LFUK a UNB
- Mickiewiczova 13, 813 69 Bratislava
- www.unb.sk
- Mária Králová, MD., PhD.
Pro mente Sana s.r.o.
- Psychiatrická ambulancia
- Halalovka 2927/63, 911 08 Trenčín
- Mária Haštová, MD
NEURES s.r.o.
- Neurologická ambulancia
- SNP 25, 053 42 Krompachy
- Renáta Smiková, MD
2. LF Univerzity Karlovy a Fakultní nemocnice v Motole
- Neurologická klinika
- V Úvalu 84, 150 18 Praha 5 - Motol
- www.fnmotol.cz
- Jakub Hort, Prof., MD, PhD
Národní ústav duševního zdraví
- Oddelení kognitivních poruch – AD centrum
- Topolová 748, 250 67 Klecany
- www.nudz.cz
- Aleš Bartoš, Doc., MD, PhD
Fakultní nemocnice u sv. Anny v Brně
- Centrum pro kognitivní poruchy, Neuro 2
- Pekařská 53, 656 91 Brno
- www.fnusa.cz
- Kateřina Sheardová, MD
Fakultní nemocnice Hradec Králové
- Neurologické oddelení
- Sokolská 581, 500 05 Hradec Králové
- www.fnhk.cz
- Martin Vališ, Prof., MD, PhD
Všeobecná fakultní nemocnice v Praze
- Neurologická klinika a Centrum klinických neurověd UK v Praze, 1. LF
- Kateřinská 30, 120 00 Praha
- www.lf1.cuni.cz
- Evžen Růžička, Prof., MD, PhD
Medizinische Universität Graz
- Universitatsklinik für Neurologie
- Auenbruggerplatz 22, 8036 Graz
- www.medunigraz.at
- Reinhold Schmidt, Prof., Dr.
Universitätsklinikum Innsbruck
- Department of Psychiatry
and Psychotherapy
- Anichstrasse 35, 6020 Innsbruck
- www.tirol-kliniken.at
- Imrich Blasko, Ao.Univ.Prof., Dr., MSc.
Tiroler Landeskrankenanstalten GmbH
- Department of Psychiatry
and Psychotherapy
- Milser Strasse 10, 6060 Hall in Tirol
- www.tirol-kliniken.at
- Josef Marksteiner, Univ.Prof., Dr.
Ordination Dr. Bancher
- Universitatsklinik für Neurologie
- Robert Hammerlinggasse 15, 3580 Horn
- Christian Bancher, Prim.Univ.Doz.Dr.
Karolinska Universitetssjukhuset Huddinge
- Minnesmottagningen M51
- SE-14186, SE-14186 Stockholm
- www.karolinska.se
- Niels Andreasen, MD, PhD
Sahlgrenska Universitetssjukhuset
- Minnesmottagningen
- Wallinsgatan 6, SE-43141 Mölndal
- www.sahlgrenska.se/sjukhus/molndals-sjukhus/
- Anne Börjesson-Hanson, Doctor, MD, PhD
Uppsala University Hospital
- Department of Geriatrics
- SE-75185, SE-75185 Uppsala
- www.akademiska.se
- Lena Kilander, MD, PhD
Skånes Universitetssjukvård Malmö
- VE Minnessjukdomar
- Simrisbanvägen 14, SE-20502 Malmö
- www.skane.se
- Henrik Östlund, MD
"Dr. Constantin Gorgos" Psychiatry Hospital Titan
- 41 Nicolae Grigorescu Boulevard, 30447 Bucharest
- www.spitalulgorgos.com
- Maria Sandulescu, MD, PhD
Wielospecjalistyczna Poradnia Lekarska Synapsis
- Czerwinskiego 8, 40 123 Katowice
- Lech Szczechowski, MD
EUROMEDIS Sp. z o.o.
- Powstańców Wielkopolskich 33a, 70 111 Szczecin
- www.euromedis.pl
- Marcin Ratajczak, MD
KO-MED Centra Kliniczne Sp. z o.o.
- Department of Psychiatry
- Kazimierza Przerwy-Tetmajera 21, 20 362 Lublin
- www.komed-ck.pl
- Roman Chwedorowicz, MD
Podlaskie Centrum Psychogeriatrii
- Swobodna 38, lok.9, 15 660 Bialystok
- www.pcp.bialystok.pl
- Jacek Dobryniewski, MD, PhD
Care Clinic
- Stanislawa Fliegera 16, 40 060 Katowice
- www.careclinic.katowice.pl
- Maciej Matuszczyk, MD
Krakowska Akademia Neurologii
- Centrum Neurologii Klinicznej
- Arianska 7/1-3, 31 505 Kraków
- www.neurologia.org.pl
- Andrzej Szczudlik, MD
PALLMED Spółka z ograniczoną odpowiedzialnością
- Poradnia Psychogeriatryczna
- Wilhelma Roentgena 3, 85 796 Bydgoszcz
- www.domsueryder.org.pl
- Robert Kucharski, MD
Indywidualna Specjalistyczna Praktyka Lekarska
- Warszawska 30, 10 082 Olsztyn
- www.zbigniew.cebulski.mp.pl
- Zbigniew Cebulski, MD
Niepubliczny Zakład Opieki Zdrowotnej NEURO-KARD
- Wierzbowa 2/2, 61 853 Poznan
- www.neurokard.pl
- Jan Ilkowski, MD
Wroclawskie Centrum Alzheimerowskie
- Aleja Hallera 190-192, 53 203 Wroclaw
- www.alzheimer.wroclaw.pl
- Marzena Zboch, MD
Universität Heidelberg
- Zentralinstitut für Seelische Gesundheit, Gerontopsychiatrie
- Quadrat J5, 68159 Mannheim
- www.zi-mannheim.de
- Lutz Fröhlich, Prof., MD.
Klinikum rechts der Isar der Technischen Universität München
- Klinik und Poliklinik fur Psychiatrie und Psychotherapie
- Ismaninger Strasse 22, 81675 München
- www.mri.tum.de
- Timo Grimmer, MD
Universitätsklinikum Ulm
- Neurologie
- Oberer Eselsberg 45, 89081 Ulm
- www.uniklinik-ulm.de
- Markus Otto, Prof., MD
Praxis Dr. Klaus Christian Steinwachs
- Neurologie und Psychiatrie
- Karolinenstrasse 57, 90402 Nürnberg
- www.praxisdrsteinwachs.de
- Klaus-Christian Steinwachs, Prof., MD
Neuro Centrum Odenwald
- Albert-Schweitzer Strasse 8, 647 11 Erbach
- www.site-neuro-centrum-odenwald.de
- Gerd Reifschneider, MD
Arzneimittelforschung Leipzig
- Paul-Gruner Strasse 63, 041 07 Leipzig
- www.www.af-leipzig.de
- Erik Strauss, MD
Univerzitetni klinični center Ljubljana
- Nevrološka klinika
- Zaloška cesta 2, 1000 Ljubljana
- www.kclj.si
- Milica Gregorič Kramberger, Assist. Prof., MD, PhD
Univerzitetni klinični center Maribor
- Ljubljanska ulica 5, 2000 Maribor
- www.ukc-mb.si
- Martin Rakuša, MD, PhD
AADvac1 nfvPPA Phase I Study
AADvac1 nfvPPA Phase I Studie
Ulm
München
Münster
Universitätsklinikum Ulm, Neurologie
- Oberer Eselsberg 45, 890 81 Ulm
- www.uniklinik-ulm.de
- Markus Otto, Prof., MD
Klinikum rechts der Isar Klinik für Psychiatrie Standort Möhlstr., Zentrum für kognitive Störungen und Rehabilitation
- Möhlstrasse 26, 81675 München
- www.mri.tum.de
- Timo Grimmer, MD
Universitätsklinikum Münster, Klinik für Neurologie mit Translationaler Neurologie
- Albert-Schweitzer-Campus 1, Geb. A1 48149 Münster
- www.ukm.de
- Thomas Duning, Prof., MD
Patient’s Room
Patientenzimmer
Pre pacienta
Pro pacienta
Patient’s Room
Patientenzimmer
Pre pacienta
Pro pacienta
Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder with an enormous unmet medical need. While the number of people suffering from AD is rising quickly, no effective treatments are available for the disorder. Symptomatic therapy, the most common therapeutic approach, is not able to stop progression of the disease. Therefore much attention is now being directed at the development of novel disease modifying therapeutic approaches, aiming to stop the disease and repair the damaged brain.
Alzheimer’s disease is characterized by the presence of neurofibrillary tangles consisting of diseased forms of protein tau and senile plaques composed of amyloid beta protein. Several studies demonstrated that distribution of neurofibrillary tangles in Alzheimer’s disease correlates well with neuronal loss and also with severity of dementia. We have therefore suggested that a therapy targeting diseased forms of tau protein has the potential to protect neurons from neurofibrillary degeneration.
AXON Neuroscience developed active immunotherapy AADvac1 targeting diseased forms of tau protein. AADvac1 stimulates the patient’s immune system to generate specific antibodies against diseased forms of tau protein and thus protects the brain from neurodegeneration.
AXON Neuroscience has successfully completed recruitment of patients in the phase II study of AADvac1, which is being conducted in several European countries. This study is designed to assess the safety and efficacy of AADvac1 in the treatment of Alzheimer's disease.
The company has also initiated the phase I study in patients with non-fluent variant of primary progressive aphasia.
The study is carried out in accordance with the ethical and scientific principles of Declaration of Helsinki, the ICH Guideline on Good Clinical Practice, the EU Clinical Trials Directive, as well as local regulations.
For more information visit AADvac1 AD Phase II study and AADvac1 nfvPPA Phase I Study.
Die Alzheimer-Krankheit ist eine altersbedingte progressive neurodegenerative Störung mit erheblichem unerfülltem Behandlungsbedarf. Trotz eines schnell wachsenden Personenkreises, der an der Alzheimer-Krankheit leidet, existiert keine effektive Behandlungsmethode dieser Störung. Die meisten Therapiemethoden sind symptomatisch, sie können aber den Krankheitsfortschritt nicht stoppen. Deshalb ist heute große Aufmerksamkeit auf die Entwicklung neuer Therapiemethoden gerichtet, die den Verlauf der Krankheit mit dem Ziel beeinflussen können, den Krankheitsfortschritt zu stoppen und die Gehirnschädigung in Ordnung zu bringen.
Für die Alzheimer-Krankheit sind sogenannte Neurofibrillenbündel, die pathologische Form vom Tau-Protein und Eiweißablagerungen, sogenannte Plaques aus Beta-Amyloid-Protein charakteristisch. Einige Studien zeigen, dass die Verteilung der Neurofibrillenbündel bei Alzheimer-Kranken mit dem Verlust von Nervenzellen und mit der Schwere der Erkrankung stark zusammenhängen. Deshalb legen wir nahe, dass eine Therapie, die sich auf pathologische Formen von Tau-Protein konzentriert, das Potenzial hat, Nervenzellen vor neurofibrillärer Degeneration zu schützen.
AXON Neuroscience entwickelte die aktive Immuntherapie AADvac1, die sich auf pathologische Tau-Proteinformen konzentriert. Der Impfstoff AADvac1 stimuliert das Immunsystem von Patienten, um spezifische Antikörper gegen pathologische Tau-Proteinformen zu bilden und so das Gehirn vor Degeneration der Nervenzellen zu schützen.
AXON Neuroscience hat erfolgreich die Patientenrekruitierung für die Klinische Studie der Phase II mit AADvac1 beendet, die in mehreren europäischen Ländern durchgeführt ist.
Das Unternehmen hat auch die Phase I Studie bei Patienten mit nicht flüssige primär progressive Aphasie begonnen.
Diese Studie ist darauf ausgelegt, die Sicherheit und Wirksamkeit des Impfstoffes AADvac1 in der Behandlung von Alzheimer-Krankheit zu bewerten.
Diese klinische Studie ist im Einklang mit ethischen Prinzipien und wissenschaftlichen Grundsätzen der Deklaration von Helsinki, der Richtlinie der Internationalen Konferenz zur Harmonisierung zur Guten Klinischen Praxis, den EU Richtlinien zu klinischen Prüfungen sowie gemäß länderspezifischer Vorschriften realisiert.
Ausführliche Informationen finden Sie in der AADvac1 AD Phase II Studie und AADvac I nfvPPA Phase I Studie.
Alzheimerova choroba je vekovo podmienené progresívne neurodegeneratívne ochorenie s enormne veľkými nenaplnenými liečebnými potrebami. Hoci sa rýchlo zvyšuje počet osôb, ktoré trpia Alzheimerovou chorobou, v súčasnosti neexistuje efektívna liečba tohto ochorenia. Najčastejším liečebným postupom je liečba zmierňujúca príznaky, ktorá však nedokáže zastaviť postup ochorenia. Preto sa v súčasnosti veľká pozornosť venuje vývoju úplne nových liečebných postupov, ktoré dokážu ovplyvniť priebeh choroby, s cieľom zastaviť postup ochorenia a opraviť poškodenia v mozgu.
Pre Alzheimerovu chorobu je typický výskyt tzv. neurofibriálnych klbiek ktoré obsahujú chorobnú formu proteínu tau a tzv. senilné plaky zložené z Beta-amyloidu. Niektoré štúdie preukázali, že výskyt neurofibriálnych klbiek u pacientov s Alzheimerovou chorobou má súvislosť so stratou nervových buniek a tiež so závažnosťou ochorenia. Preto sme navrhli liečbu zameranú na patologickú formu proteínu tau, ktorá má predpoklady ochrániť nervové bunky pred neurofibriálnou degeneráciou.
Spoločnosť AXON Neuroscience vyvinula aktívnu imunoterapiu AADvac1, ktorá je zameraná na chorobné formy proteínu tau. Vakcína AADvac1 stimuluje pacientov imunitný systém s cieľom vytvoriť špecifické protilátky proti tomuto proteínu tau a tým chrániť mozog pred degeneráciou nervových buniek.
Spoločnosť AXON Neuroscience úspešne ukončila nábor pacientov pre AADvac1 fázu II klinického skúšania, ktoré sa vykonáva v niekoľkých európskych krajinách. Účelom tohto skúšania je doplniť údaje o bezpečnosti a posúdiť účinnosť vakcíny AADvac1 pri liečbe Alzheimerovej choroby.
Spoločnosť taktiež zahájila fázu I klinického skúšania pacientov s nonfluentnou primárnou progresívnou afáziou.
Toto skúšanie sa vykonáva v súlade s etickými a vedeckými zásadami Helsinskej deklarácie, Smerníc Medzinárodnej konferencie pre harmonizáciu o správnej klinickej praxi, Smerníc EÚ o klinickom skúšaní, a s miestnymi predpismi.
Podrobnejšie informácie sa uvádzajú v štúdii AADvac1 AD Fáza II a AADvac1 nfvPPA Fáza I.
Alzheimerova nemoc je věkově podmíněná progresivní neurodegenerativní porucha s enormně velkými nenaplněnými léčebnými potřebami. Ačkoli se rychle roste počet osob, které trpí Alzheimerovou nemocí, neexistuje efektivní léčba této poruchy. Nejčastějším léčebným postupem je symptomatická terapie, která však nedokáže zastavit postup onemocnění. Proto se v současnosti věnuje velká pozornost vývoji zcela nových léčebných postupů, které dokážou ovlivnit průběh choroby, s cílem zastavit postup onemocnění a napravit poškození v mozku.
Pro Alzheimerovu nemoc je typický výskyt tzv. neurofibrilárních klubek, která pozůstávají z patologických forem proteinu tau a tzv. senilní plaky složené z proteinu beta-amyloidu. Některé studie prokázaly, že výskyt neurofibrilárních klubek u pacientů s Alzheimerovou nemocí souvisí se ztrátou nervových buněk a rovněž se závažností onemocnění. Proto jsme navrhli léčbu zaměřenou na patologickou formu proteinu tau, která má předpoklady ochránit nervové buňky před neurofibrilární degenerací.
Společnost AXON Neuroscience vyvinula aktivní imunoterapii AADvac1, která se zaměřuje na patologické formy proteinu tau. Vakcína AADvac1 stimuluje pacientův imunitní systém s cílem vytvořit specifické protilátky proti patologickým formám proteinu tau, a tím chránit mozek před degenerací nervových buněk.
Společnost AXON Neuroscience úspěšně ukončila nábor pacientů pro fázi II klinického zkoušení AADvac1, které se provádí v několika evropských zemích. Účelem tohoto zkoušení je posouzení bezpečnosti a účinnosti vakcíny AADvac1 při léčbě Alzheimerovy nemoci.
Společnost také zahájila fázi I klinických hodnocení pacientů s nonfluentnou primární progresivní afázií.
Toto zkoušení se provádí v souladu s etickými a vědeckými zásadami Helsinské deklarace, směrnic Mezinárodní konference pro harmonizaci o správné klinické praxi, směrnic EU o klinickém testování, a s místními předpisy.
Podrobnější informace jsou uvedeny ve studii AADvac1 AD Fáze II a AADvac1 nfvPPA Fáze I.
Press room
Events
- Upcoming events
- Past events
- There are currently no events to display.
- The 14th International Conference on Alzheimer's and Parkinson's Diseases (ADPD)
March 26-31, 2019Lisbon, Portugaladpd.kenes.com/2019
- 21st International Symposium on Signal Transduction at the Blood-Brain Barriers
- September 19-21, 2018Arad, Romaniahttp://bbb2018.uvvg.ro
- XXII International Mass Spectrometry Conference
- August 26-31, 2018Florence, Italyhttp://www.imsc2018.it
- Alzheimer's Association International Conference
- July 22-26, 2018Chicago, USAwww.alz.org/aaic
- 21 st International Conference Analytical Methods and Human Health
- June 17-20, 2018Jasna, Slovakiawww.isss2018.sk/symposium/welcome
- 2nd Meeting of THE SOCIETY FOR CSF ANALYSIS AND CLINICAL NEUROCHEMISTRY
- June 7-8, 2018Amsterdam, Netherlandswww.neurochem.info/html/meeting
- 25th Annual PNIRS Scientific Meeting
- June 6-9, 2018Miami, USAwww.pnirs.org/meetings/index.cfm
- 8th Regional Biophysics Conference
- May 16-20, 2018Zrece, Sloveniawww.rbc2018.si/index.html
- EUROTAU 2018
- April 26-27, 2018Lille, Francewww.lucbuee.fr/crbst_10
- XV Discussions in Structural Molecular Biology
- March 22-24, 2018Nove Hrady, Czech Republicwww.structbio.org/xv-discussions-structural-molecular-biology
- 10th Clinical Trials on Alzheimer´s Disease
- November 1-4, 2017Boston, USAwww.ctad-alzheimer.com
- Alzheimer´s Association International Conference
- July 16-20, 2017London, Englandwww.alz.org/aaic
- The 13th International Conference on Alzheimer´s and Parkinson´s Diseases (ADPD)
- March 29-April 2, 2017Vienna, Austriawww.adpd2017.kenes.com
- 9th Clinical Trials on Alzheimer´s Disease
- December 8-10, 2016San Diego, USAwww.ctad-alzheimer.com
- 10th International Conference on Frontotemporal Dementias
- August 31-September 2, 2016Munich, Germanywww.icftd2016.de
- Alzheimer´s Association International Conference
- July 24-28, 2016Toronto, Canadawww.alz.org/aaic
- The 1st meeting of The Society for CSF Analysis and Clinical Neurochemistry
- May 12-13, 2016Gothenburg, Swedenhttp://www.neurochem.info/html/meeting
- Biopharma Asia Convention 2016
- March 22-24, 2016Singaporewww.terrapinn.com/exhibition/bio-asia/
- 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy
- March 9-12, 2016Athens, Greecewww.ad-springfield.com
- 10th Annual Therapeutic Partnerships
- November 18-20, 2015Boston, USAwww.iirusa.com/therapeuticareapartnership
- Clinical Trials on Alzheimer´s Disease
- November 5-7, 2015Barcelona, Spainwww.ctad-alzheimer.com
The seventh conference on Clinical Trials on Alzheimer's Disease in Philadelphia last month covered everything from a sprinkling of new trial results to a new focus on tau PET imaging to a plea from former FDA honcho Rusty Katz that trialists stop obsessing over disease modification and aggressively pursue big therapeutic effects instead. Madolyn Rogers and Gabrielle Strobel close out their report on the meeting with a look at the role brain amyloid plays in AD, and a review of what new treatments may be in store for 2015.
- Alzheimer´s Association International Conference
- July 18-23, 2015Washington D.C., USAwww.alz.org/aaic
Join international investigators, clinicians and care providers as they gather to share the latest study results, theories and discoveries that will help bring the world closer to breakthroughs in dementia science.
- The 12th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders
- March 18-22, 2015Nice, Francewww.kenes.com/adpd
The 12th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PDTM 2015) will build on the well-earned reputation of previous AD/PDTM meetings for unraveling the mechanisms and improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases. Conference attendees will gain unique and powerful insights into the latest research, developments, and treatments.
- 7th Clinical Conference on Alzheimer‘s Disease
- November 20-22, 2014Philadelphia, USAwww.ctad.fr
Alzheimer’s disease is one of the most important health challenges facing aging populations worldwide. The development of the next generation of Alzheimer’s disease drugs is becoming essential to face up to this challenge. We learned in San Diego of new pathways identified with biomarkers, facilitating novel trial designs for studies of tau-based therapies and other disease-modifying drugs including immunotherapy.
- Alzheimer's Association International Conference® 2014
- July 12-17, 2014Copenhagen, Denmarkwww.alz.org/aaic
Join us from July 12-17 in Copenhagen for AAIC 2014®, where thousands of researchers from more than 60 countries will gather to reveal the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.
- 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy 2014
- March 26-29, 2014Geneva, Switzerlandwww.siumed.edu/cme/alzheimer
Leading scientists will discuss new targets and drugs for the treatment of Alzheimer’s disease and novel approaches to current therapy. An oral communication session will be open to young scientists.We expect approximately 1500 participants, mostly neurologists, psychiatrists, geriatricians and pharmacologists.
- Alzheimer's Association International Conference® 2013
- July 13-18, 2013Boston, USAhttp://www.alz.org/aaic/about/
The Alzheimer's Association International Conference (AAIC) is the world's premier forum for the reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. As a part of the Association's research program, AAIC serves as a catalyst for generating new knowledge about Alzheimer's and fostering a vital, collegial research community.
- 6th Clinical Trials Conference on Alzheimer's Disease 2013
- November 14-16, 2013San Diego, USAhttp://www.ctad.fr/12-press/
The 6th annual CtaD conference will relate experiences from international teams covering every stage of clinical trials in Alzheimer’s Disease. From animal models to human trials, CtaD 2013 provides an opportunity to learn about the latest results in drug trials as well as important topics such as internet screening of cognition to recruit for clinical trials, designing drug trials taking into account neuropsychiatric symptoms of AD, down syndrome as well as ethical issues and methodological considerations.
- AD/PD 2013
- March 6-10, 2013Florence, Italywww.kenes.com/adpd/
AD/PD™ 2013, the 11th International Conference on Alzheimer’s and Parkinson’s Disease, co-organized by Abraham Fisher, Israel Hanin, Roger Nitsch and Manfred Windisch, is a landmark event bringing together over 3,000, neuroscientists, pharmacologists and clinicians to study the hot topics, similarities and differences and scientific breakthroughs associated with Alzheimer’s Disease, Parkinson’s Disease and related neurological disorders, and to evaluate advances that might ameliorate many of these diseases.
- 8th International Winter Conference on Alzheimer's Disease 2012
- December 7-10, 2012Zuers, Austriawww.ad-zuers.com
In a snowy mountain town in Austria, 75 scientists met from 7-10 December 2012 for the 8th International Winter Conference on Alzheimer’s Disease. They traded data and discussion of treatment approaches in the kind of cooped-up, homey atmosphere that brings down barriers when a diverse group of scientists stay together from breakfast until dinner to present, question, and debate science.
Press Releases
- Axon Neuroscience to launch world’s first crowdfunded vaccine against COVID-19, September 17, 2020
- Axon Announces Positive Pre-Clinical Results for its Peptide Vaccine (ACvac1) Against Novel Coronavirus, September 9, 2020
- Axon Neuroscience has a promising peptide vaccine against COVID-19 in development, April 9, 2020
- Axon presented positive phase II trial results of AADvac1 at AAT-AD/PD 2020. April 2, 2020
- Axon announces positive results from Phase II ADAMANT trial for AADvac1 in Alzheimer’s Disease, September 2019
- Axon Neuroscience appoints Michal Fresser as Group CEO, August 2019
- AXON meets the first milestone in an nfvPPA Phase 1 study with AADvac1 – Bratislava, December 12, 2017
- AXON’s Tau Vaccine has Completed Phase II Enrolment in Alzheimer’s – London, July 17, 2017
- AXON’s Tau Vaccine Offers Potential for Treating Frontotemporal Dementia Patients – Vienna, April 1, 2017
- AXON presented at CTAD the additional results from the 18 months Follow up of the Phase I Study – San Diego, December 13, 2016
- AXON´s Alzheimer´s tau vaccine phase 1 study results published in Lancet Neurology – Bratislava, December 9, 2016
- AXON´s Pioneering Tau Vaccine Against Alzheimer´s Started Phase II – Bratislava, June 22
- AXON Presented Its Tau Vaccine in Two Presentations at 14th AAT Conference – Athens, March 11, 2016
- Horizon 2020 Marie Sklodowska-Curie Actions Grant Awarded To AXON Neuroscience – Bratislava, November 10, 2015
- AXON´s AADvac1 Tau Vaccine One Of The Hot Topics At CTAD 2015 Conference – Barcelona, November 10, 2015
- Prof. Novak to become Scientific Advisory Board Chairman, Assoc. Prof. Norbert Zilka new CSO - Bratislava, October 1, 2015
- Encouraging Results of AXON's Tau Vaccine Advance Alzheimer's Therapy - Washington, D.C., July 23, 2015
- AXON Neuroscience’s vaccine to halt Alzheimer’s finishes Phase 1 clinical trial - Bratislava, July 2, 2015
- MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody for Alzheimer's disease Therapy
- Ground-breaking discovery of the first candidate tau vaccine against Alzheimer's disease - AD/PD Florence 2013
- Bachem and AXON Neurosciences sign contract for finished dosage forms of peptide-protein conjugate
Career
Job Positions
There are no current openings, please check back soon
Connect with us
Thank you for contacting AXON Neuroscience.
We will get back to you within a few days.
Find out more about AXON Neuroscience job opportunities or send us your Resume via webform below.
Contract Length
3 years
Institution
AXON Neuroscience R&D Services SE, Bratislava
Department
Centre for Diagnostic and Validation Platforms
Job Description
A postdoctoral position is available for a period of 3 years at Slovak biotech company AXON Neuroscience R&D Services SE. Centre for Diagnostic and Validation Platforms focuses on development of novel animal models for Alzheimer’s and Parkinson’s disease.
We are looking for highly motivated candidates with a strong background in neuroscience and excellent expertise in transgenic technologies (pronuclei microinjections), embryofreezing and embryotransfer and stereotaxic surgery.
Experience with laboratory animals, strong scientific aspirations and English are required.
Contact Information
- Dr. Norbert Žilka
- zilka@axon-neuroscience.eu
- AXON Neuroscience R&D
Services SE
Dvořákovo nábrežie 10
811 02 Bratislava - www.axon-neuroscience.eu
Contract Length
3 years
Institution
AXON Neuroscience R&D Services SE, Bratislava
Department
Centre for Diagnostic and Validation Platforms
Job Description
The position is available in the new animal facility at Slovak biotech company - AXON Neuroscience R&D Services SE. Centre for Diagnostic and Validation Platforms focuses on development of novel animal models for Alzheimer’s and Parkinson’s disease.
The successful candidate will perform and oversee all veterinary activities in the rodent facility, oversee the breeding plan and its accurate fulfilment, coordinate the technical staff and assume responsibility for work safety and hazard protection.
Experience with laboratory animals and English language required.
Contact Information
- Dr. Norbert Žilka
- zilka@axon-neuroscience.eu
- AXON Neuroscience R&D
Services SE
Dvořákovo nábrežie 10
811 02 Bratislava - www.axon-neuroscience.eu
Contract Length
3 years
Institution
AXON Neuroscience R&D Services SE, Bratislava
Department
Neuroproteomics Laboratory
Job Description
The candidate should have PhD in the field biology/biochemistry and an excellent experience and track record in proteomics, including chromatography and mass spectrometry. He/she should have knowledge based methods competence in protein isolation, identifications of modifications and protein-protein interactions. Experience in structural analysis is advantageous (e.g. mass spectrometry identification of native crosslinks, hydrogen-deuterium exchange, surface mapping by protein modification, etc.).
The successful candidate should be highly motivated, actively seeking and implementing knowledge from broad spectrum of life sciences and able to fully manage own project(s).
In addition, he/she should have high command of written and oral English, computer literacy and ability to work in teams.
Contact Information
- Dr. Norbert Žilka
- zilka@axon-neuroscience.eu
- AXON Neuroscience R&D
Services SE
Dvořákovo nábrežie 10
811 02 Bratislava - www.axon-neuroscience.eu
Overview
We recognize that creativity is at the heart of success
At AXON Neuroscience we work together every day to discover, develop, and deliver breakthrough therapies for patients suffering from Alzheimer’s disease.
We provide our employees with challenging workplace where each position offers an opportunity for professional development. Passion for innovation and novelty plays leading roles in our work.
We encourage thinking outside the box
We offer exciting and challenging careers within a collaborative and knowledge-driven environment where ideas and skills are highly valued; and where individual contributions are recognised and rewarded.
Employees take advantage of opportunities to attend international conferences, participate in international professional associations, and publish their research in scientific journals.
Employees create a can-do atmosphere
We are always on the lookout for people who are extremely capable, talented, and enthusiastic, for strongly motivated people who are looking for an environment that values all of these qualities in its employees.
Join us and you will have an opportunity to grow and develop your career with the company. If you have an interest in becoming a member of our team, please submit your CV for a position.
Contact
Contact us
AXON Neuroscience SE
- Arch. Makariou & Kalogreon 4
Nicolaides Sea View City
Block C, 5th floor
Office 506
6016 LARNACA
CYPRUS - +357 2425 2636
- +357 2425 2637
- office@axon-neuroscience.eu
AXON Neuroscience CRM Services SE
- Dvořákovo nábrežie 10
811 02 BRATISLAVA
SLOVAK REPUBLIC - +421 2 2092 1620
- +421 2 2092 1624
- office@axon-neuroscience.eu
AXON Neuroscience R&D Services SE
- Dvořákovo nábrežie 10
811 02 BRATISLAVA
SLOVAK REPUBLIC - +421 2 2092 1620
- +421 2 2092 1624
- office@axon-neuroscience.eu
Partners Contact
+421 2 2092 1620
partners@axon-neuroscience.euMedia Contact
+421 911 098 117
media@axon-neuroscience.euData Protection Officer
+421 2 2092 1632
dpo@axon-neuroscience.eu
